The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab

Oncologist

Volumn 16, Issue 1, 2011, Pages 53-60

  Scartozzi, Mario ^a   Mandolesi, Alessandra ^b   Giampieri, Riccardo ^c   Bittoni, Alessandro ^c   Pierantoni, Chiara ^a   Zaniboni, Alberto ^d   Galizia, Eva ^e   Giustini, Lucio ^f   Silva, Rosa Rita ^e   Bisonni, Renato ^f   Berardi, Rossana ^a   Biscotti, Tommasina ^b   Biagetti, Simona ^b   Bearzi, Italo ^b   Cascinu, Stefano ^a  

^a AO Ospedali Riuniti Università   (Italy)

^b Department of Anatomia Patologica ^*  (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d Oncologia Medica   (Italy)

^e Ospedale Profili   (Italy)

^f Ospedale di Fermo   (Italy)

Author keywords

Cetuximab therapy; Colorectal cancer; HER 3 expression; Wild type K RAS colon cancer

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RECEPTOR, ERBB-3; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79952607191     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0119     Document Type: Article

References (30)

1. Goldberg RM, Rothenberg ML, Van Cutsem E et al. The continuum of care: A paradigm for the management of metastatic colorectal cancer. The Oncologist 2007;12:38-50.
2. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. J Clin Oncol 2007;357:2040-2048.
3. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
4. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
5. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
6. Lièvre A, Bachet JB, Boige V et al. Kras mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-379.
7. Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-1169.
8. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 2008;15:413-448.
9. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER-3. Br J Cancer 2007;97:453-457.
10. Campbell MR, Amin D, Moasser MM. HER3 comes of age: New insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010;16:1373-1383.
11. Wheeler DL, Huang S, Kruser TJ et al. Mechanisms of acquired resistance to cetuximab: Role of HER(ErbB) family members. Oncogene 2008;27:3944-3956.
12. Buck E, Eyzaguirre A, Haley JD et al. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 2006;5:2051-2059.
13. Xu JM, Han Y, Duan HQ et al. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. J Cancer Res Clin Oncol 2009;135:771-782.
14. Frolov A, Schuller K, Tzeng CW et al. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther 2007;6:548-554.
15. Jain A, Penuel E, Mink S et al. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res 2010;70:1989-1999.
16. Prigent SA, Lemoine NR, Hughes CM. et al. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene 1992;7:1273-1278.
17. Tanner B, Hasenclever D, Stern K et al. ErB-3 predicts survival in ovarian cancer. J Clin Oncol 2006;24:4317-4323.
18. Lurje G, Nagashima F, Zhang W. et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 2008;14:7884-7895.
19. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005;6:279-286.
20. Scartozzi M, Bearzi I, Mandolesi A et al. Epidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: A fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 2009;9:303-310.
21. Perrone F, Lampis A, Orsenigo M et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009;20:84-90.
22. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenetic activation of RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-2648.
23. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-5712.
24. Loupakis F, Pollina L, Stasi I et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009;27:2622-2629.
25. Scartozzi M, Bearzi I, Pierantoni C et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007;25:3930-3935.
26. Köhne C, Stroiakovski D, Chang-Chien C et al. Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial [abstract 4068]. J Clin Oncol 2009;27(15 suppl):15.
27. Scartozzi M, Mandolesi A, Giampieri R et al. Insulin-like growth factor 1 expression correlates with clinical outcome inK-RASwild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer 2010;127:1941-1947.
28. Leung SP, Griffith OL, Masoudi H et al. Clinical utility of type 1 growth factor receptor expression in colon cancer. Am J Surg 2008;195:604-610.
29. Kountourakis P, Pavlakis K, Psyrri A et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 2006;6:46-54.
30. Sergina NV, Rausch M, Wang D et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:43-441.